NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading INCY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Growth in Jakafi, Opzelura, and Hematology/Oncology sales: metric not reported.
View ThesisRevenue growth is accelerating — up about 21% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIncyte's growth in Jakafi, Opzelura, and Hematology/Oncology sales must continue to justify the price. Revenue grew 38% year over year, and the last quarter beat expectations significantly. It trades at 14× P/E versus a peer median of 20×. This suggests the price reflects less growth than expected. A risk is that if guidance is cut, it could hurt credibility. Peer multiples imply a price about 23% above where it trades; this read is provisional.
Trailing returns as of 2026-07-31. INCY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering INCY (as of Jul 2026).
Based on 11 Wall Street analysts offering 12-month price targets for INCY in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Positive results support advancement of late-stage pipeline.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $119.52
The last 12 months of price, then the range of analyst 12-month targets from today’s $119.52.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase Hematology and Oncology sales
Increased sales guidance supports growth in Hematology and Oncology.
Rating downgrade may impact investor sentiment and valuation.
Threatens: Increase Hematology and Oncology sales
Sales guidance miss impacts growth expectations.
Advances: Increase Hematology and Oncology sales
Better-than-expected sales support growth objectives.
Advances: Complete acquisition and integration of Vega Therapeutics
Acquisition of Vega Therapeutics aligns with growth strategy.
Advances: Complete acquisition and integration of Vega Therapeutics
Collaboration enhances growth potential through new product development.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Positive data presentation supports late-stage pipeline advancement.
